| Literature DB >> 34896918 |
Na Sun1, Yingying Yang2, Hui Miao2, Peter Redublo3, Hongtao Liu4, Wenfei Liu5, Yen-Wen Huang4, Pai-Chi Teng6, Ceng Zhang7, Ryan Y Zhang4, Matthew Smalley4, Peng Yang4, Shih-Jie Chou4, Kevin Huai4, Zhicheng Zhang4, Yi-Te Lee4, Jasmine J Wang6, Jing Wang4, Icy Y Liang4, Tiffany X Zhang4, Dongyun Zhang3, Li Liang8, Paul S Weiss5, Edwin M Posadas6, Timothy Donahue9, J Randolph Hecht10, Martin S Allen-Auerbach11, Emily K Bergsland12, Thomas A Hope13, Renjun Pei14, Yazhen Zhu15, Hsian-Rong Tseng16, Anthony P Heaney17.
Abstract
Circulating tumor cell (CTC) clusters are present in cancer patients with severe metastasis, resulting in poor clinical outcomes. However, CTC clusters have not been studied as extensively as single CTCs, and the clinical utility of CTC clusters remains largely unknown. In this study, we aim sought to explore the feasibility of NanoVelcro Chips to simultaneously detect both single CTCs and CTC clusters with negligible perturbation to their intrinsic properties in neuroendocrine tumors (NETs). We discovered frequent CTC clusters in patients with advanced NETs and examined their potential roles, together with single NET CTCs, as novel biomarkers of patient response following peptide receptor radionuclide therapy (PRRT). We observed dynamic changes in both total NET CTCs and NET CTC cluster counts in NET patients undergoing PRRT which correlated with clinical outcome. These preliminary findings suggest that CTC clusters, along with single CTCs, offer a potential non-invasive option to monitor the treatment response in NET patients undergoing PRRT.Entities:
Keywords: Circulating tumor cell clusters; Circulating tumor cells; Nanostructured substrates; Neuroendocrine tumor; Peptide receptor radionuclide therapy
Mesh：
Substances：
Year: 2021 PMID： 34896918 PMCID： PMC8900541 DOI： 10.1016/j.bios.2021.113854
Source DB: PubMed Journal: Biosens Bioelectron ISSN： 0956-5663 Impact factor: 12.545